Quality of Life After Treatment for Bladder Cancer


About this study

The purpose of this study is to compare general and disease-specific quality of life outcomes at 6, 12, 24, and 36 months after treatment for localized bladder cancer using the PROMIS-29 and the Bladder Cancer Index (BCI) respectively and to identify patient level characteristics that may influence quality of life outcomes after treatment for localized bladder cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • ≥ 18 years of age;
  • Have pathologically confirmed, clinically localized, bladder cancer;
  • Be willing to complete a survey in English before starting definitive treatment (surgery or radiation);
  • Able to give consent.

Exclusion Crtieria:

  • None.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Gettman, M.D.

Open for enrollment

Contact information:

Mikayla Schmidt CCRP

(507) 422-5768


Jacksonville, Fla.

Mayo Clinic principal investigator

Paul Young, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mark Tyson, M.D., M.P.H.

Open for enrollment

Contact information:

Emily Stricklin

(480) 574-2946


More information


Publications are currently not available